The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC – Neal Shore
Neal Shore, MD, FACS presents his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity and antineoplastic therapies and potentially prolonging overal survival.
